生物活性肽-单核细胞迁移抑制因子研究进展

程浩; 芮耀诚; 章越凡; 李铁军

doi:10.3969/j.issn.1006-0111.2015.01.005

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

1.
安徽中医药大学药学院, 安徽合肥 230012
2.
第二军医大学药学院药理学教研室, 上海 200433
3.
安徽中医药大学药学院, 安徽合肥 230012;第二军医大学药学院药理学教研室, 上海 200433

基金项目: 国家科技重大专项项目:防治心肌缺血的抗炎短肽候选化合物研究(2013ZX09103001-005)

Research progress of bioactive peptide monocyte locomotion inhibitory factor

1.
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
2.
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
3.
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China;Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

摘要: 单核细胞迁移抑制因子(monocyte locomotion inhibitory factor,MLIF)是阿米巴原虫产生的具有抗炎作用的五肽。体内、外研究发现,MLIF可以发挥抗炎和免疫保护作用,对类风湿关节炎、神经损伤、心肌缺血、脑缺血及痴呆具有良好的保护作用。研究证明MLIF通过NF-κB 和MAPK信号通路调节炎症反应和免疫保护。笔者对MLIF的来源和生物活性做一综述。
- 单核细胞迁移抑制因子 /
- 炎症 /
- 免疫 /
- 生物活性肽
Abstract: Monocyte locomotion inhibitory factor(MLIF)was an anti-inflammatory pentapeptide produced by Entamoeba histolytica.In vivo and in vitro study showed that MLIF displayed anti-inflammatory and immune protection effects and MLIF had protective effects on rheumatoid arthritis,nerve injury,myocardial ischemia,cerebral ischemia and Alzheimer's disease.Studies had shown that MLIF regulated inflammatory response and immune protection through NF-κB and MAPK signal pathways.The sources and biological activities of MLIF were reviewed in this paper.
- monocyte locomotion inhibitory factor /
- inflammation /
- immune /
- bioactive peptide

[1]	王竹青, 李八方.生物活性肽及其研究进展[J].中国海洋药物杂志,2010,29(2):60-68.
[2]	Kretschmer RR,Collado ML,Pacheco MG,et al.Inhibition of human monocyte locomotion by products of Entamoeba histolytica[J].Parasite Immunol,1985,7:527-543.
[3]	López-Osuna M,Cárdenas G,Isario J,et al.Induction of protective immunity against experimental amebic abscess of the liver (EAAL) using the monocyte locomotion inhibitory factor (MLIF) produced by Entamoeba histolytica:a preliminary report[J].Arch Med Res,2000, 31(4):S110-S111.
[4]	Jiang HF,Li J,Zhao X,et al.Determination of an unstable pentapeptide,monocyte locomotion inhibitory factor,in dog blood by LC-MS/MS:application to a pharmacokinetic study[J].J Pharm Biomed Anal,2013,83:305-313.
[5]	Giménez-Schr JA,Arenas E,Díaz L,et al.Effect of the monocyte locomotion inhibitory factor (MLIF) produced by Entamoeba histolytica on the expression of cell adhesion molecules in the skin of guinea pigs[J].Arch Med Res,2000,31(4 Suppl):S92-S93.
[6]	Godina-Gonzalez S,Furuzawa-Carballeda J,Utrera-Barillas D,et al.Amebic monocyte locomotion inhibitory factor peptide ameliorates inflammation in CIA mouse model by downregulation of cell adhesion,inflammation/chemotaxis,and matrix metalloproteinases genes[J].Inflamm Res,2010,59(12):1041-1051.
[7]	Velázquez JR,Garibay-Martínez L,Martínez-Tejada P,et al.An amebic anti-inflammatory peptide down-regulates ex vivo IL-1β expression in patients with rheumatoid arthritis[J].Reumatol Clin,2012,8(6):315-320.
[8]	章越凡,芮耀诚,李铁军,等.五肽代谢物在制备抗炎药物中的应用[P].中国专利,CN 103611149 A,2014-03-05.
[9]	Utrera-Barillas D,Velazquez JR,Enciso A,et al.An anti-inflammatory oligopeptide produced by Entamoeba histolytica down-regulates the expression of pro-inflammatory chemokines[J].Parasite Immunol,2003,25(10),475-482.
[10]	Silva-García R,Estrada-García I,Ramos-Payán R,et al.The effect of an anti-inflammatory pentapeptide produced by Entamoeba histolytica on gene expression in the U-937 monocytic cell line[J].Inflamm Res,2008,57(4):145-150.
[11]	Morales-Martínez ME,Silva-García R,Soriano-Correa C,et al.The Cys-Asn-Ser carboxyl-terminal end group is the pharmacophore of the amebic anti-inflammatory monocyte locomotion inhibitory factor (MLIF)[J].Mol Biochem Parasitol,2008,158(1):46-51.
[12]	Barrientos-Salcodo C,Rico-Rosillo G,Giménez-Scherer JA,et al.Computational study of the electronic structure characterization of a novel anti-inflammatory tripeptide derived from monocyte locomotion inhibitory factor (MLIF)-pentapeptide[J].Eur J Med Chem,2009,44 (8):3114-3119.
[13]	Rojas-Dotor S,Perez-Ramos J,Gimenez-Scherer,et al.Effect of the monocyte locomotion inhibitory factor (MLIF) produced by E.histolityca on cytokines and chemokine receptors in T CD4⁺ lymphocytes[J].Bio Res,2009,42 (4):415-425.
[14]	Rojas-Dotor S,Rico G,Pérez J,et al.Cytokine expression in CD4⁺ cells exposed to the monocyte locomotion inhibitory factor produced by Entamoeba histolytica[J].Parasitol Res,2006,98(5):493-495.
[15]	Rico G,Leandro E,Rojas S,et al.The monocyte locomotion inhibitory factor produced by Entamoeba histolytica inhibits induced nitric oxide production in human leukocytes[J].Parasitol Res,2003,90 (4),264-267.
[16]	Zhang Y,Chen J,Li F,et al.A pentapeptide monocyte locomotion inhibitory factor protects brain ischemia injury by targeting the eEF1A1/endothelial nitric oxide synthase pathway[J].Stroke,2012,43(10):2764-2773.
[17]	杨鹏远,芮耀诚,章越凡.多肽小分子在制备防治缺血性脑血管病药物中的应用[P].中国专利,CN 101361961 A,2009-2-11.
[18]	章越凡,芮耀诚,李铁军,等.五肽代谢物及其在制备防治缺血性脑血管疾病药物中的应用[P].中国专利,CN 103611149 A,2014-03-05.
[19]	芮耀诚,李铁军,杨鹏远,等.多肽小分子MLIF在制备防治心肌缺血药物中的应用[P].中国专利,CN 101612384A,2009-12-30.
[20]	李铁军,芮耀诚,章越凡,等.一种五肽的部分代谢物用于制备抗心肌缺血产品的新用途[P].中国专利,CN 103203009 A,2013-07-17.
[21]	Yao J,Xu Y,Ji F,et al.Protective effects of MLIF analogs on cerebral ischemia-reperfusion injury in rats[J].Peptides,2011,32(5):1047-1054.
[22]	Bermeo G,Ibarra A,García E,et al.Monocyte locomotion inhibitory factor produced by E.histolytica improves motor recovery and develops neuroprotection after traumatic injury to the spinal cord[J].Biomed Res Int,2013,2013:340727.
[23]	李铁军,芮耀诚,章越凡,等.一种五肽及其代谢物用于制备抗痴呆产品的新用途[P].中国专利,CN 103191407,2013-07-10.
[24]	Silva-Garcia R,Rico-Rosillo G.Anti-inflammatory defense mechanisms of Entamoeba histolytica[J].Inflamm Res,2011,60(2):111-117.
[25]	Sasaki M,Kashima M,Watanabe A,et al.Differential regulation of metalloproteinase production,proliferation and chemotaxis of human lung fibroblasts by PDGF,interleukin-1beta and TNF-alpha[J].Mediators Inflamm,2000,9(3-4):155-160.
[26]	Gharaee-Kermani M,Phan SH.Role of cytokines and cytokine therapy in wound healing and fibrotic diseases[J].Curr Pharm Des,2001,7(11):1083-1103.
[27]	Velazquez JR.The monocyte locomotion inhibitory factor an anti-inflammatory peptide;therapeutics originating from amebic abscess of the liver[J].Recent Pat Endocr Metab Immune Drug Discov,2011,5(1):7-12.
[28]	Silva-García R,Rico-Rosillo G.Anti-inflammatory defense mechanisms of Entamoeba histolytica[J].Inflamm Res,2011,60(2):111-117.

[1]	赵全公, 王国坤, 徐志云. 虾青素通过激活Nrf2/HO-1通路抑制瓣膜间质细胞钙化 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202412057
[2]	施乔, 韩贵焱, 张俊腾, 刘娜. 新型Hsp90抑制剂的设计合成及其抗真菌和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(3): 124-135. doi: 10.12206/j.issn.2097-2024.202501019
[3]	吴若南, 叶爽, 李墨晨轩, 缪震元, 罗川. 冬凌草甲素磺酰脲衍生物的设计与抗炎活性的研究 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202401048
[4]	卢熠菲, 宋佳, 沈红霞, 赵庆杰. 新型苦参碱衍生物的设计合成与体外抗炎活性研究 . 药学实践与服务, 2025, 43(): 1-8. doi: 10.12206/j.issn.2097-2024.202503005
[5]	吴若南, 汤文敏, 高林, 吴岳林, 罗川, 缪震元. RRx-001衍生物的合成和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202408053
[6]	李惠萍, 陈璐, 张琪金, 黄宝康. 紫苏叶挥发油成分的生物合成、含量测定及生物活性研究进展 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202412058
[7]	曹金发, 钟玲, 何苗, 田泾. 炎症性肠病合并心房颤动患者的用药分析与监护 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202403004
[8]	竺东杰, 贺新征, 邹杰, 余史丹, 李红霞. 雷公藤甲素对大鼠脑缺血再灌注损伤的影响及机制研究 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202311021
[9]	周文艳, 胡珊珊, 张万年, 庄春林. Keap1-Nrf2通路在炎症疾病中的研究进展 . 药学实践与服务, 2025, 43(3): 97-108, 116. doi: 10.12206/j.issn.2097-2024.202405013
[10]	赖立勇, 夏天爽, 徐圣焱, 蒋益萍, 岳小强, 辛海量. 中药青蒿抗氧化活性的谱效关系研究 . 药学实践与服务, 2024, 42(5): 203-210, 216. doi: 10.12206/j.issn.2097-2024.202211012
[11]	张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳. 基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
[12]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[13]	白学鑫, 陈玉平, 盛春泉, 武善超. 具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 503-507. doi: 10.12206/j.issn.2097-2024.202405009
[14]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
[15]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[16]	岳春华, 贲永光, 王海桥. 基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
[17]	顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩. 侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
[18]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[19]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[20]	张广雨, 杜晶, 刘梦珍, 朱丹妮, 闫慧, 刘冲. 新斯的明与山莨菪碱联合应用对肺型氧中毒的保护作用及其机制的研究 . 药学实践与服务, 2024, 42(10): 433-438, 444. doi: 10.12206/j.issn.2097-2024.202310049

点击查看大图

计量

文章访问数: 3757
HTML全文浏览量: 360
PDF下载量: 134
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

Research progress of bioactive peptide monocyte locomotion inhibitory factor

计量

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

1. 安徽中医药大学药学院, 安徽合肥 230012

2. 第二军医大学药学院药理学教研室, 上海 200433

3. 安徽中医药大学药学院, 安徽合肥 230012;第二军医大学药学院药理学教研室, 上海 200433

English Abstract

Research progress of bioactive peptide monocyte locomotion inhibitory factor

全文HTML

目录

留言板

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

Research progress of bioactive peptide monocyte locomotion inhibitory factor

计量

出版历程

生物活性肽-单核细胞迁移抑制因子研究进展

doi: 10.3969/j.issn.1006-0111.2015.01.005

1. 安徽中医药大学药学院, 安徽 合肥 230012 2. 第二军医大学药学院药理学教研室, 上海 200433 3. 安徽中医药大学药学院, 安徽 合肥 230012;第二军医大学药学院药理学教研室, 上海 200433

English Abstract

Research progress of bioactive peptide monocyte locomotion inhibitory factor

全文HTML

目录

1. 安徽中医药大学药学院, 安徽合肥 230012

2. 第二军医大学药学院药理学教研室, 上海 200433

3. 安徽中医药大学药学院, 安徽合肥 230012;第二军医大学药学院药理学教研室, 上海 200433